Astellas Pharma Inc. v. Apotex Inc.
1:16-cv-00976
Overview
Parties
Defendant
Apotex Corp. Operating Company
Represented By
1 Attorneys ListedAbrams & Bayliss LLP
20 Montchanin Road, Suite 200
Plaintiff
Astellas Pharma Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Interested Party
Apotex Inc. Operating Company
Represented By
1 Attorneys ListedAbrams & Bayliss LLP
20 Montchanin Road, Suite 200
Counter Defendant
Astellas Pharma Global Development, Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Astellas Ireland Co., Ltd. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,342,117 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 7,982,049 B2 | US Continuation / Sibling | View Official Patent → |
| π―π΅ Japan | JP 2001332914 | Japan Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 2003037881 A1 | PCT World Application | View Official Patent → |
Astellas Pharma Inc. v. Sawai Pharmaceutical Co., Ltd.
Astellas Pharma Inc. v. Aurobindo Pharma Ltd.
Astellas Pharma Inc. v. Windlas Healthcare Pvt. Ltd.
Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA), Inc.
Astellas Pharma Inc. v. Actavis Elizabeth LLC
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7342117
Ξ±-form or Ξ²-form crystal of acetanilide derivative
|
Filed: 2002-10-20
Issued: 2008-03-11
|
Expired (Term Ended)
+371d PTA
Expires: 2023-10-26
|
|
|
US7982049
Ξ±-form or Ξ²-form crystal of acetanilide derivative
|
Filed: 2008-01-14
Issued: 2011-07-19
|
Expired (Term Ended)
Expires: 2026-04-07
|
|
|
US8835474
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
|
Filed: 2011-05-27
Issued: 2014-09-16
|
Active (4.5 yrs remaining)
Expires: 2031-05-27
|
|
|
USRE44872
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
|
Filed: 2003-11-04
Issued: 2014-04-29
|
Expired (Term Ended)
+44d PTA
Expires: 2023-12-18
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+371 days) / Cellect Scrutiny β Over 371 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
6
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings